Advertisement
Research Article

The Reno-Vascular A2B Adenosine Receptor Protects the Kidney from Ischemia

  • Almut Grenz,

    Affiliations: Department of Pharmacology and Toxicology, Tübingen University Hospital, Tübingen, Germany, Mucosal Inflammation Program, Department of Anesthesiology and Perioperative Medicine, University of Colorado Health Sciences Center, Denver, Colorado, United States of America

    X
  • Hartmut Osswald,

    Affiliation: Department of Pharmacology and Toxicology, Tübingen University Hospital, Tübingen, Germany

    X
  • Tobias Eckle,

    Affiliations: Mucosal Inflammation Program, Department of Anesthesiology and Perioperative Medicine, University of Colorado Health Sciences Center, Denver, Colorado, United States of America, Department of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Tübingen, Germany

    X
  • Dan Yang,

    Affiliation: Department of Biochemistry and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts, United States of America

    X
  • Hua Zhang,

    Affiliation: Department of Pharmacology and Toxicology, Tübingen University Hospital, Tübingen, Germany

    X
  • Zung Vu Tran,

    Affiliation: Department of Biostatistics, University of Colorado, Denver, Colorado, United States of America

    X
  • Karin Klingel,

    Affiliation: Department of Molecular Pathology, Tübingen University Hospital, Tübingen, Germany

    X
  • Katya Ravid,

    Affiliation: Department of Biochemistry and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts, United States of America

    X
  • Holger K Eltzschig mail

    To whom correspondence should be addressed. E-mail: holger.eltzschig@uchsc.edu

    Affiliations: Mucosal Inflammation Program, Department of Anesthesiology and Perioperative Medicine, University of Colorado Health Sciences Center, Denver, Colorado, United States of America, Department of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Tübingen, Germany

    X
  • Published: June 24, 2008
  • DOI: 10.1371/journal.pmed.0050137

About the Authors

Almut Grenz, Hartmut Osswald, Hua Zhang
Department of Pharmacology and Toxicology, Tübingen University Hospital, Tübingen, Germany
Almut Grenz, Tobias Eckle, Holger K Eltzschig
Mucosal Inflammation Program, Department of Anesthesiology and Perioperative Medicine, University of Colorado Health Sciences Center, Denver, Colorado, United States of America
Tobias Eckle, Holger K Eltzschig
Department of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Tübingen, Germany
Dan Yang, Katya Ravid
Department of Biochemistry and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts, United States of America
Zung Vu Tran
Department of Biostatistics, University of Colorado, Denver, Colorado, United States of America
Karin Klingel
Department of Molecular Pathology, Tübingen University Hospital, Tübingen, Germany

Corresponding Author

Email: holger.eltzschig@uchsc.edu

Competing Interests

Bayer HealthCare has patented the use of the A2BAR agonist BAY 60-6583 in the treatment of different medical conditions. The authors are not associated with Bayer HealthCare and are not involved in the patent application. The authors report no competing interests.

Author Contributions

AG, HO, TE, KR, and HKE designed the experiments/the study. AG, TE, DY, HZ, KK, and KR collected data or did experiments for the study. AG, ZVT, KK, KR, and HKE analyzed the data. AG, HO, ZVT, KR, and HKE contributed to writing the paper.